Clinical Trial Update: Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of JTT-705 at three doses (300, 600, 900 mg) versus placebo in adults with Type II hyperlipidaemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type Ii Hyperlipidaemia

Drugs mentioned

• JTT-705

Snippet

Sponsor: Japan Tobacco Inc. | Conditions: Type II Hyperlipidaemia | Phase 2 | Status: COMPLETED